Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma

Journal of Molecular Diagnostics

Volumn 19, Issue 3, 2017, Pages 404-416

  Mellert, Hestia ^a   Foreman, Trudi ^a   Jackson, Leisa ^a   Maar, Dianna ^b   Thurston, Scott ^a   Koch, Kristina ^a   Weaver, Amanda ^a   Cooper, Samantha ^b   Dupuis, Nicholas ^a   Sathyanarayana, Ubaradka G ^a   Greer, Jakkie ^a   Hahn, Westen ^a   Shelton, Dawne ^b   Stonemetz, Paula ^b   Pestano, Gary A ^a  

^a BIODESIX INC   (United States)

^b Bio Rad Laboratories Digital Biology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE AND 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; PROTEIN; UNCLASSIFIED DRUG; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN TYROSINE KINASE; ANAPLASTIC LYMPHOMA KINASE; CELL CYCLE PROTEIN; EML4 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; PROTEIN P21; SERINE PROTEINASE;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EXON; GENE DELETION; GENETIC VARIATION; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; ONCOGENE RAS; SENSITIVITY AND SPECIFICITY; BLOOD EXAMINATION; CANCER PATIENT; CLINICAL EVALUATION; CLINICAL PRACTICE; GENE MUTATION; GENETIC SCREENING; HUMAN TISSUE; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG TUMOR; MUTATION; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SERINE ENDOPEPTIDASES;

EID: 85018496544     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2016.11.004     Document Type: Article

References (50)

1. 1 Weber, B., Meldgaard, P., Hager, H., Wu, L., Wei, W., Tsai, J., Khalil, A., Nexo, E., Sorensen, B.S., Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer [Internet], 14, 2014, 294 doi: 10.1186/1471-2407-14-294.
2. 2 Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
3. 3 Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. 4 Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H., EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004), 13306–13311.
5. 5 Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007), 169–181.
6. 6 Sahnane, N., Frattini, M., Bernasconi, B., Zappa, F., Schiavone, G., Wannesson, L., Antonelli, P., Balzarini, P., Sessa, F., Mazzucchelli, L., Tibiletti, M.G., Martin, V., EGFR and KRAS mutations in ALK-positive lung adenocarcinomas: biological and clinical effect. Clin Lung Cancer 17 (2016), 56–61.
7. 7 Paxton, A., Is molecular AP testing in sync with guidelines?. CAP Today, November 2014, 01.
8. 8 Ignatiadis, M., Lee, M., Jeffrey, S.S., Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res 21 (2015), 4786–4800.
9. 9 Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6 (2016), 479–491.
10. 10 Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 (2013), 472–484.
11. 11 Sacher, A.G., Paweletz, C., Dahlberg, S.E., Alden, R.S., O'Connell, A., Feeney, N., Mach, S.L., Janne, P.A., Oxnard, G.R., Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2 (2016), 1014–1022.
12. 12 Sozzi, G., Conte, D., Leon, M., Ciricione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., Pierotti, M.A., Pastorino, U., Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21 (2003), 3902–3908.
13. 13 Korpanty, G.J., Graham, D.M., Vincent, M.D., Leighl, N.B., Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol [Internet], 4, 2014, 204 doi: 10.3389/fonc.2014.00204.
14. 14 Oxnard, G.R., Paweletz, C.P., Kuang, Y., Mach, S.L., O'Connell, A., Messineo, M.M., Luke, J.J., Butaney, M., Kirschmeier, P., Jackman, D.M., Janne, P.A., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20 (2014), 1698–1705.
15. 15 Mok, T., Wu, Y.L., Lee, J.S., Yu, C.J., Sriuranpong, V., Sandoval-Tan, J., Ladrera, G., Thongprasert, S., Srimuninnimit, V., Liao, M., Zhu, Y., Zhou, C., Fuerte, F., Margono, B., Wen, W., Tsai, J., Truman, M., Klughammer, B., Shames, D.S., Wu, L., Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
16. 16 Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sanchez, J.M., Porta, R., Ponce-Aix, S., Moran, T., Carcereny, E., Felip, E., Bover, I., Insa, A., Reguart, N., Isla, D., Vergnenegre, A., de Marinis, F., Gervais, R., Corre, R., Paz-Ares, L., Morales-Espinosa, D., Viteri, S., Drozdowskyj, A., Jordana-Ariza, N., Ramirez-Serrano, J.L., Molina-Vila, M.A., Rosell, R., Spanish Lung Cancer Group. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 1 (2015), 149–157.
17. 17 Salgia, R., Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol 11 (2015), 489–500.
18. 18 Yu, J., Kane, S., Wu, J., Benedettini, E., Li, D., Reeves, C., Innocenti, G., Wetzel, R., Crosby, K., Becker, A., Ferrante, M., Cheung, W.C., Hong, X., Chirieac, L.R., Sholl, L.M., Haack, H., Smith, B.L., Polakiewicz, R.D., Tan, Y., Gu, T.L., Loda, M., Zhou, X., Comb, M.J., Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15 (2009), 3023–3028.
19. 19 Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., Haggstrom, D., Felip, E., Kim, J.H., Frewer, P., Cantarini, M., Brown, K.H., Dickinson, P.A., Ghiorghiu, S., Ranson, M., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
20. 20 Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., Koh, Y., Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res 21 (2015), 3552–3560.
21. 21 Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
22. 22 Choi, Y.L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., Kurashina, K., Hatanaka, H., Ueno, T., Takada, S., Yamashita, Y., Sugiyama, Y., Ishikawa, Y., Mano, H., Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68 (2008), 4971–4976.
23. 23 Shaw, A.T., Yeap, B.Y., Mino-Kenudson, M., Digumarthy, S.R., Costa, D.B., Heist, R.S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., Settleman, J., Kobayashi, S., Mark, E.J., Rodig, S.J., Chirieac, L.R., Kwak, E.L., Lynch, T.J., Iafrate, A.J., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
24. 24 Boch, C., Kollmeier, J., Roth, A., Stephan-Falkenau, S., Misch, D., Gruning, W., Bauer, T.T., Mairinger, T., The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open [Internet], 3, 2013, e002560 doi: 10.1136/bmjopen-2013-002560.
25. 25 Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J., Ruiz, M.G., Giaccone, G., Sequist, L.V., Johnson, B.E., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15 (2009), 5267–5273.
26. 26 Suda, K., Tomizawa, K., Mitsudomi, T., Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29 (2010), 49–60.
27. 27 Hindson, B.J., Ness, K.D., Masquelier, D.A., Belgrader, P., Heredia, N.J., Makarewicz, A.J., et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83 (2011), 8604–8610.
28. 28 Beaver, J.A., Jelovac, D., Balukrishna, S., Cochran, R.L., Croessmann, S., Zabransky, D.J., Wong, H.Y., Valda Toro, P., Cidado, J., Blair, B.G., Chu, D., Burns, T., Higgins, M.J., Stearns, V., Jacobs, L., Habibi, M., Lange, J., Hurley, P.J., Lauring, J., VanDenBerg, D.A., Kessler, J., Jeter, S., Samuels, M.L., Maar, D., Cope, L., Cimino-Mathews, A., Argani, P., Wolff, A.C., Park, B.H., Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20 (2014), 2643–2650.
29. 29 Takeshita, T., Yamamoto, Y., Yamamoto-Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., Iwase, H., Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci 106 (2015), 1582–1589.
30. 30 Maus, M.K., Stephens, C., Zeger, G., Grimminger, P.P., Huang, E., Identification of novel variant of EML4-ALK fusion gene in NSCLC: potential benefits of the RT-PCR method. Int J Biomed Sci 8 (2012), 1–6.
31. 31 Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C., Barrett, J.C., Jänne, P.A., Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol 34 (2016), 3375–3382.
32. 32 Reckamp, K.L., Melnikova, V.O., Karlovich, C., Sequist, L.V., Camidge, D.R., Wakelee, H., Perol, M., Oxnard, G.R., Kosco, K., Croucher, P., Samuelsz, E., Vibat, C.R., Guerrero, S., Geis, J., Berz, D., Mann, E., Matheny, S., Rolfe, L., Raponi, M., Erlander, M.G., Gadgeel, S., A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11 (2016), 1690–1700.
33. 33 Paci, M., Maramotti, S., Bellesia, E., Formisano, D., Albertazzi, L., Ricchetti, T., Ferrari, G., Annessi, V., Lasagni, D., Carbonelli, C., De Franco, S., Brini, M., Sgarbi, G., Lodi, R., Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64 (2009), 92–97.
34. 34 Marchetti, A., Palma, J.F., Felicioni, L., De Pas, T.M., Chiari, R., Del Grammastro, M., Filice, G., Ludovini, V., Brandes, A.A., Chella, A., Malorgio, F., Guglielmi, F., De Tursi, M., Santoro, A., Crino, L., Buttitta, F., Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 10 (2015), 1437–1443.
35. 35 Piotrowska, Z., Niederst, M.J., Karlovich, C.A., Wakelee, H.A., Neal, J.W., Mino-Kenudson, M., Fulton, L., Hata, A.N., Lockerman, E.L., Kalsy, A., Digumarthy, S., Muzikansky, A., Raponi, M., Garcia, A.R., Mulvey, H.E., Parks, M.K., DiCecca, R.H., Dias-Santagata, D., Iafrate, A.J., Shaw, A.T., Allen, A.R., Engelman, J.A., Sequist, L.V., Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 5 (2015), 713–722.
36. 36 Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., Dunning, M.J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., Rosenfeld, N., Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368 (2013), 1199–1209.
37. 37 Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
38. 38 Douillard, J.Y., Ostoros, G., Cobo, M., Ciuleanu, T., Cole, R., McWalter, G., Walker, J., Dearden, S., Webster, A., Milenkova, T., McCormack, R., Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9 (2014), 1345–1353.
39. 39 Mostert, B., Sieuwerts, A.M., Bolt-de Vries, J., Kraan, J., Lalmahomed, Z., van Galen, A., van der Spoel, P., de Weerd, V., Ramirez-Moreno, R., Smid, M., Verhoef, C., IJzermans, J.N., Gratama, J.W., Sleijfer, S., Foekens, J.A., Martens, J.W., mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol Oncol 9 (2015), 920–932.
40. 40 Sieuwerts, A.M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F.E., Stouthard, J.M., Dirix, L.Y., van Dam, P.A., Van Galen, A., de Weerd, V., Kraan, J., van der Spoel, P., Ramirez-Moreno, R., van Deurzen, C.H., Smid, M., Yu, J.X., Jiang, J., Wang, Y., Gratama, J.W., Sleijfer, S., Foekens, J.A., Martens, J.W., mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17 (2011), 3600–3618.
41. 41 Antonarakis, E.S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J.C., Chen, Y., Mohammad, T.A., Chen, Y., Fedor, H.L., Lotan, T.L., Zheng, Q., De Marzo, A.M., Isaacs, J.T., Isaacs, W.B., Nadal, R., Paller, C.J., Denmeade, S.R., Carducci, M.A., Eisenberger, M.A., Luo, J., AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
42. 42 Best, M.G., Sol, N., Kooi, I., Tannous, J., Westerman, B.A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., Ylstra, B., Ameziane, N., Dorsman, J., Smit, E.F., Verheul, H.M., Noske, D.P., Reijneveld, J.C., Nilsson, R.J., Tannous, B.A., Wesseling, P., Wurdinger, T., RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28 (2015), 666–676.
43. 43 Rodriguez, M., Silva, J., Lopez-Alfonso, A., Lopez-Muniz, M.B., Pena, C., Dominguez, G., Garcia, J.M., Lopez-Gonzalez, A., Mendez, M., Provencio, M., Garcia, V., Bonilla, F., Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 53 (2014), 713–724.
44. 44 Kalluri, R., The biology and function of exosomes in cancer. J Clin Invest 126 (2016), 1208–1215.
45. 45 Jung, K., Fleischhacker, M., Rabien, A., Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature. Clin Chim Acta 411 (2010), 1611–1624.
46. 46 Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014, 224ra24.
47. 47 Rodia, M.T., Ugolini, G., Mattei, G., Montroni, I., Zattoni, D., Ghignone, F., Veronese, G., Marisi, G., Lauriola, M., Strippoli, P., Solmi, R., Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget 7 (2016), 30295–30306.
48. 48 Vogelstein, B., Kinzler, K.W., Digital PCR. Proc Natl Acad Sci U S A 96 (1999), 9236–9241.
49. 49 Sasaki, T., Rodig, S.J., Chirieac, L.R., Janne, P.A., The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46 (2010), 1773–1780.
50. 50 Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F.O., Hesch, R.D., Knippers, R., DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001), 1659–1665.